Mindray non-China revenue accounts now for 50%, I had no idea (I guess partly helped by the rough year they are having in China with volumes down 20%). It seems fairly diversified too.
Similar to other high quality a-shares growthy names, the stock has gone nowhere in 5 years (like Inovance, Proya etc).
They quickly got to 80-100x PE in 1 year, and spent the next 4 years slowly derating to 25-30x while net income doubled/tripled. The market was right.